Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine Extended Release and Mindfulness in Traumatically Stressed Youth
NCT03258476Phase 4Withdrawn
- Sponsor
- UConn Health
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of guanfacine in post-traumatic stress disorder (PTSD), sponsored by UConn Health. Planned start Mar 2019; status: withdrawn.
02
Drugs
guanfacine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03258476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258476.